Biologit provides a purpose‑built, AI‑driven platform that consolidates global and local scientific literature—including subscription databases, websites, and print—into a single, compliant interface for pharmacovigilance teams. Its transparent, auditable AI scores relevance, extracts safety‑critical data, and offers machine‑translation, delivering up to 50‑60% time savings while meeting GxP, GAMP, CFR 21, and EU AI Act requirements. The solution integrates with existing PV tools and scales across products, teams, and markets.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmacovigilance teams must continuously monitor a vast array of global and local scientific literature to detect safety signals, but traditional manual processes are labor‑intensive, fragmented across many sources, and difficult to keep compliant with GxP, GAMP, CFR 21, and emerging AI regulations.
Solution
Biologit offers a single, purpose‑built platform that automates literature monitoring for pharmacovigilance. The system aggregates subscription‑based databases, public websites, and even print sources, applying proprietary, auditable AI to identify relevant articles and extract safety‑critical information. Machine‑translation expands coverage to non‑English publications, while built‑in compliance frameworks ensure the workflow is inspection‑ready under GxP, GAMP, CFR 21 and the EU AI Act. Results are delivered through configurable dashboards and analytics, enabling faster signal detection, reduced manual effort (up to 50‑60% time savings), and scalable oversight across products, teams, and markets. Integration hooks allow seamless connection to existing PV tools and data pipelines.
Target Audience
Biologit serves large pharma companies, CROs and PV service providers, as well as biotech and mid‑size pharmaceutical firms that need enterprise‑grade, compliant literature monitoring without building custom solutions.
Features
- AI‑driven relevance scoring and extraction with transparent, validated models (no black‑box components)
- End‑to‑end coverage of global databases, local journals, websites, and print sources in a single interface
- Machine‑translation of non‑English literature to ensure comprehensive local surveillance
- Compliance‑by‑design architecture aligned with GxP, GAMP, CFR 21 and EU AI Act requirements
- Scalable workflow engine supporting multi‑product, multi‑team, and multi‑market monitoring
- API and integration connectors for easy linking with existing pharmacovigilance systems
- Real‑time dashboards and analytics that turn monitoring data into actionable safety insights